クオリプス株式会社
Osaka, JP · 2 known investors
Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
Founders & leadership
TK
Takayuki KusanagiRepresentative Director, President & CEO
TT
Tadayuki TanimuraDirector, Executive Vice President
KH
Kazuyoshi HiraoDirector, Executive Vice President & Chief Business Officer
YS
Yoshiki SawaDirector, Chief Medical Science Officer
Investors · 2
Frequently asked questions
- What does クオリプス株式会社 do?
- Cuorips develops regenerative medicine products based on human iPS cell technology, including its heart muscle cell sheet "Heart®" (Rehart) for treating severe heart failure caused by ischemic cardiomyopathy, along with catheter-based therapies and compound drugs (YS series). The Japan-based company, spun out of Osaka University research, also builds cell mass-manufacturing infrastructure (VMaCS) and is listed on the Tokyo Stock Exchange Growth market.
- Who are クオリプス株式会社's investors?
- クオリプス株式会社's investors include Kyoto University Innovation Capital, Nippon Venture Capital.
- Where is クオリプス株式会社 headquartered?
- クオリプス株式会社 is headquartered in Osaka, JP.